Floatz logo

Avatrombopag

Cirrhosis Of Liver

Tongji HospitalSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

134 Active assets in the Cirrhosis Of Liver cohort.

View all 50

Same molecule, other indications

Avatrombopag is also rated in:

thrombocytopeniaActive
BB
Indicative · Phase 4
70 / 100
View asset →
liver failureDormant
BB
Indicative · Phase 4
65 / 100
View asset →
chemotherapy-induced toxicityDormant
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →